FDA Slaps Clinical Hold On Celyad's Phase 1 Colorectal Cancer Trial

by Vandana Singh, Benzinga Editor

March 2, 2022 9:25 AM | 1 min read | Make a Comment

The FDA has issued a clinical hold on Celyad Oncology SA's CYAD CYAD-101-002 (KEYNOTE-B79) Phase 1b trial due to insufficient information to assess risk to study subjects.
As previously disclosed, the Company announced that it was voluntarily pausing the CYAD-101-002 trial to investigate reports of two fatalities in the study.
Celyad Oncology is a clinical-stage biotechnology company focused on discovering and developing chimeric antigen receptor T cell (CAR T) therapies for cancer.
The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for hematological malignancies and solid tumors.
Price Action: CYAD shares closed 15.4% lower at $2.26 on Tuesday.

Posted In: Biotech News Penny Stocks FDA General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.